Transcriptomic and proteomic analysis of quiescent epimastigotes as a resource for investigating Trypanosoma cruzi persistence

by Olmo F, Hesketh A, Hage H, Monneuse J-M, Taylor MC, Costa FC, Da Silva C, Bequet F, Escudié F, Mercer D, Saliou A, Chatelain E, Kelly JM, Abi-Ghanem J. Communications Biology 2026. doi:10.1038/s42003-026-11251-3

Summary: Eliminating a non-replicating Trypanosoma cruzi sub-population that can persist after treatment for Chagas disease is a key challenge in drug discovery. The authors of this manuscript describe the transcriptome and proteome profiles of a low-proliferative sub-population of epimastigote forms of the parasite isolated from exponentially growing cultures. This partially quiescent sub-population was characterised by down-regulation of genes/proteins involved in translation, transcription, metabolism, mitochondrial function, and DNA replication, and by up-regulation of proteins that promote exit from the cell cycle in other organisms. Differential expression was considerably more pronounced at a protein than an RNA level. These data provide a resource that can be exploited to dissect the mechanistic basis of quiescence, as a step towards refining the drug-development screening cascade.

Access article

The post Transcriptomic and proteomic analysis of quiescent epimastigotes as a resource for investigating Trypanosoma cruzi persistence first appeared on DNDi.

Ajude os pacientes negligenciados

Até o momento, desenvolvemos nove tratamentos para doenças negligenciadas, salvando milhões de vidas. Temos o objetivo de disponibilizar 25 novos tratamentos em nossos primeiros 25 anos. Você pode nos ajudar!

Organização internacional, sem fins lucrativos, que desenvolve tratamentos seguros, eficazes e acessíveis para os pacientes mais negligenciados.

DNDi Global

Entre em contato

DNDi pelo mundo

Apoie a DNDi

Faça uma doação!

Trabalhe conosco

Oportunidades

Exceto para imagens, filmes e marcas registradas que estão sujeitos aos Termos de Uso da DNDi, o conteúdo deste site está licenciado sob uma Licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license.